Optimal timing of antiviral therapy for chronic HBV-infected patients with normal ALT
10.3760/cma.j.cn501113-20201126-00630
- VernacularTitle:ALT正常的慢性HBV感染者的抗病毒治疗时机选择
- Author:
Honglian GUI
1
;
Qing XIE
Author Information
1. 上海交通大学医学院附属瑞金医院感染科 200025
- Keywords:
Hepatitis B virus;
Alanine aminotransferase;
Hepatocellular carcinoma;
Antiviral therapy
- From:
Chinese Journal of Hepatology
2020;28(12):988-991
- CountryChina
- Language:Chinese
-
Abstract:
Whether to initiate antiviral therapy in chronic hepatitis B virus (HBV) infected population with normal alanine aminotransferase (ALT) is hot and difficult issue. Improvements in drug availability and affordability have paved the way for more data, which may become a medium for confirming whether this population needs antiviral treatment. Regardless of whether HBeAg is positive or negative, there are still a considerable number of patients with chronic HBV infection with normal ALT, who have obvious liver inflammation, fibrosis or cirrhosis and need to start antiviral therapy. Liver biopsy or non-invasive techniques can be used as diagnostic tools to begin an early treatment in population with liver fibrosis and inflammation.
